[HTML][HTML] Next generation GLP-1/GIP/glucagon triple agonists normalize body weight in obese mice
Objective Pharmacological strategies that engage multiple mechanisms-of-action have
demonstrated synergistic benefits for metabolic disease in preclinical models. One …
demonstrated synergistic benefits for metabolic disease in preclinical models. One …
Managing weight and glycaemic targets in people with type 2 diabetes—How far have we come?
Introduction As the vast majority of people with type 2 diabetes (T2D) are also overweight or
obese, healthcare professionals (HCP) are faced with the task of addressing both weight …
obese, healthcare professionals (HCP) are faced with the task of addressing both weight …
Les approches thérapeutiques non invasives de l'obésité: hier, aujourd'hui et demain
M Galmiche, P Déchelotte - Nutrition clinique et métabolisme, 2022 - Elsevier
Résumé Face à l'augmentation de la prévalence de l'obésité et ses conséquences en
termes de santé publique, il est nécessaire de toujours mieux en comprendre la …
termes de santé publique, il est nécessaire de toujours mieux en comprendre la …
Novel Drugs for Diabetes Therapy
T Heise - From Obesity to Diabetes, 2022 - Springer
Since the first use of insulin 100 years ago, there have been marked improvements in
diabetes therapy including, but not limited to, the development of oral antidiabetic agents …
diabetes therapy including, but not limited to, the development of oral antidiabetic agents …